Not a good buy right now for an impatient entry: near-term momentum is weakening (negative, expanding MACD) while options positioning skews bearish (very high put open interest).
While longer-term trend structure is constructive (bullish moving-average stack), the stock is trading below the key pivot (8.722) and lacks a fresh catalyst this week.
A better “right now” buy setup would be a decisive reclaim of 8.72 and push toward 9.31; at the current 8.38, risk of a dip to 8.14/7.77 is still meaningful.
Technical Analysis
Trend/structure: Bullish moving averages (SMA_5 > SMA_20 > SMA_200) suggest the broader trend is up.
Momentum: MACD histogram is below zero and negatively expanding (-0.00917), indicating downside momentum is building in the short term.
RSI: RSI_6 at 48.49 is neutral—no oversold bounce signal.
Levels: Price (8.38) is below the pivot (8.722).
Support: 8.136 (S1), then 7.774 (S2)
Resistance: 9.309 (R1), then 9.671 (R2)
Pattern-based outlook (provided): higher chance of small drift lower next day/week, but a positive 1-month skew (+17.6%), reinforcing “good longer-term story, choppy near-term entry.”
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning/sentiment: Open Interest Put-Call Ratio = 5.19 (puts greatly outweigh calls) → bearish or heavy hedging bias.
Activity: Today’s options volume is 0 (thin/illiquid tape today), so sentiment inference is more from outstanding positioning than fresh flow.
Volatility: 30D IV ~296% with IV percentile ~72.7 / IV rank ~65.1 → very elevated implied volatility, implying the market is pricing high uncertainty/risk; options are expensive.
Technical Summary
Sell
5
Buy
6
Positive Catalysts
after Q3, citing enthusiasm around Emrosi launch and higher peak revenue forecast.
Neutral/Negative Catalysts
No news/catalyst in the past week to override weakening short-term momentum.
Profitability pressure: net loss widened and EPS declined YoY; gross margin also fell.
Options market positioning is notably put-heavy (high put OI vs calls), which often aligns with cautious/bearish near-term expectations.
Technical momentum is currently deteriorating (MACD negative and expanding) while price sits below pivot, increasing odds of a support retest (8.14/7.77).
Wall Street analysts forecast DERM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DERM is 14 USD with a low forecast of 13 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast DERM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DERM is 14 USD with a low forecast of 13 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.350
Low
13
Averages
14
High
16
Current: 8.350
Low
13
Averages
14
High
16
Alliance Global
Buy
maintain
$10 -> $16
AI Analysis
2025-11-13
Reason
Alliance Global
Price Target
$10 -> $16
AI Analysis
2025-11-13
maintain
Buy
Reason
Alliance Global raised the firm's price target on Journey Medical to $16 from $10 and keeps a Buy rating on the shares post the Q3 report. The firm cites enthusiasm in the Emrosi launch for the target boost. It increased its peak revenue forecast to $250M from $200M for the drug.
H.C. Wainwright
Brandon Folkes
Buy
initiated
$13
2025-08-25
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$13
2025-08-25
initiated
Buy
Reason
H.C. Wainwright analyst Brandon Folkes initiated coverage of Journey Medical with a Buy rating and $13 price target. The firm believes the company's Emrosi has demonstrated clinical superiority to market leader Oracea in rosacea. This creates the potential for prescription demand and revenue pull through to exceed current consensus expectations, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DERM
